Health insurance company Clover Health (NASDAQ:CLOV) announced in Q3 CY2025, with sales up 50.1% year on year to $496.7 million. Its GAAP loss of $0.05 per share was $0.02 below analysts’ consensus ...

“Clover transformed into a commercial-stage, vaccines-focused biotech company with proven R&D capabilities in 2022. In 2023, we are focused on launching our vaccine in multiple countries and working ...

Okay. All right. Thanks for joining us here today. With us today, we have Clover Health. On stage is CFO, Peter Kuipers. I believe he's going to start off with the presentation. Thank you, Jonathan.

WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial ...